Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 170

1.

Impact of HER-2-targeted therapy on overall survival in patients with HER-2 positive metastatic breast cancer.

Berghoff AS, Bago-Horvath Z, Dubsky P, Rudas M, Pluschnig U, Wiltschke C, Gnant M, Steger GG, Zielinski CC, Bartsch R.

Breast J. 2013 Mar-Apr;19(2):149-55. doi: 10.1111/tbj.12070. Epub 2013 Jan 27.

PMID:
23350584
2.

Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.

Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, Ellis C, Florance A, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J.

J Clin Oncol. 2012 Jul 20;30(21):2585-92. doi: 10.1200/JCO.2011.35.6725. Epub 2012 Jun 11.

PMID:
22689807
3.

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, Ellis C, Casey M, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J.

J Clin Oncol. 2010 Mar 1;28(7):1124-30. doi: 10.1200/JCO.2008.21.4437. Epub 2010 Feb 1.

PMID:
20124187
4.

Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases.

Bartsch R, Berghoff A, Pluschnig U, Bago-Horvath Z, Dubsky P, Rottenfusser A, DeVries C, Rudas M, Fitzal F, Dieckmann K, Mader RM, Gnant M, Zielinski CC, Steger GG.

Br J Cancer. 2012 Jan 3;106(1):25-31. doi: 10.1038/bjc.2011.531. Epub 2011 Nov 29.

5.

A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.

Larsen PB, Kümler I, Nielsen DL.

Cancer Treat Rev. 2013 Nov;39(7):720-7. doi: 10.1016/j.ctrv.2013.01.006. Epub 2013 Mar 5. Review.

PMID:
23481218
6.

Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study.

Kaufman PA, Brufsky AM, Mayer M, Rugo HS, Tripathy D, Yood MU, Feng S, Wang LI, Quah CS, Yardley DA.

Breast Cancer Res Treat. 2012 Oct;135(3):875-83. doi: 10.1007/s10549-012-2209-z. Epub 2012 Aug 26.

7.

Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer.

Gori S, Montemurro F, Spazzapan S, Metro G, Foglietta J, Bisagni G, Ferzi A, Silva RR, Gamucci T, Clavarezza M, Stocchi L, Fabi A, Cognetti F, Torrisi E, Crivellari D.

Ann Oncol. 2012 Jun;23(6):1436-41. doi: 10.1093/annonc/mdr474. Epub 2011 Oct 29.

PMID:
22039084
8.

[Clinical value of trastuzumab in the treatment of lapatinib-resistant HER2-positive metastatic breast cancer].

Ma F, Xu BH, Li HH, Li Q, Zhang P, Yuan P, Wang JY, Fan Y, Li Q.

Zhonghua Zhong Liu Za Zhi. 2013 Jul;35(7):521-4. Chinese.

PMID:
24257305
9.

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.

Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, Press MF, Maltzman J, Florance A, O'Rourke L, Oliva C, Stein S, Pegram M.

J Clin Oncol. 2009 Nov 20;27(33):5538-46. doi: 10.1200/JCO.2009.23.3734. Epub 2009 Sep 28.

PMID:
19786658
10.

Prognostic factors of brain metastases from breast cancer: impact of targeted therapies.

Braccini AL, Azria D, Thezenas S, Romieu G, Ferrero JM, Jacot W.

Breast. 2013 Oct;22(5):993-8. doi: 10.1016/j.breast.2013.05.011. Epub 2013 Jul 3.

PMID:
23831232
11.

Time to first tumor progression as outcome predictor of a second trasuzumab-based therapy beyond progression in HER-2 positive metastatic breast cancer.

Metro G, Giannarelli D, Gemma D, Lanzetta G, Ciccarese M, Papaldo P, Gamucci T, Lorusso V, Mottolese M, Magnolfi E, Cognetti F, Fabi A.

Breast J. 2010 Jan-Feb;16(1):66-72. doi: 10.1111/j.1524-4741.2009.00849.x. Epub 2009 Nov 2.

PMID:
19889170
12.

Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.

Wang YC, Morrison G, Gillihan R, Guo J, Ward RM, Fu X, Botero MF, Healy NA, Hilsenbeck SG, Phillips GL, Chamness GC, Rimawi MF, Osborne CK, Schiff R.

Breast Cancer Res. 2011;13(6):R121. doi: 10.1186/bcr3067. Epub 2011 Nov 28.

13.

HER-3 status by immunohistochemistry in HER-2-positive metastatic breast cancer patients treated with trastuzumab: correlation with clinical outcome.

Gori S, Foglietta J, Mameli MG, Stocchi L, Fenocchio D, Anastasi P, Iacono D, Del Sordo R, Basurto C, De Angelis V, Sidoni A.

Tumori. 2012 Jan-Feb;98(1):39-44. doi: 10.1700/1053.11498.

PMID:
22495700
14.

Biological subtypes and survival outcomes in breast cancer patients with brain metastases (study of the Anatolian Society of Medical Oncology).

Kaplan MA, Isikdogan A, Koca D, Kucukoner M, Gumusay O, Yildiz R, Dayan A, Demir L, Geredeli C, Kocer M, Arslan UY, Inal A, Unal OU, Mert AG, Bilici M, Ozkan M, Elkiran ET, Yaman S, Durnalı AG, Suner A, Alici S, Tarhan MO, Boruban C, Urakci Z, Buyukberber S.

Oncology. 2012;83(3):141-50. doi: 10.1159/000338782. Epub 2012 Jul 18.

PMID:
22814315
15.

Clinical outcomes and cardiac safety of continuous antiHer2 therapy in c-erbB2-positive metastatic breast cancer patients.

Fedele P, Orlando L, Schiavone P, Ciccarese M, Forcignanò RC, Calvani N, Marino A, Nacci A, Sponziello F, Mazzoni E, Rizzo P, Lorusso V, Cinieri S.

J Chemother. 2013 Dec;25(6):369-75. Epub 2013 Dec 6.

PMID:
24392943
16.

Second-Line Treatment of Her2-Positive Metastatic Breast Cancer: Trastuzumab beyond Progression or Lapatinib? A Population Based Cohort Study.

Hammerman A, Greenberg-Dotan S, Feldhamer I, Bitterman H, Yerushalmi R.

PLoS One. 2015 Sep 16;10(9):e0138229. doi: 10.1371/journal.pone.0138229. eCollection 2015.

17.

Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death.

Le Scodan R, Jouanneau L, Massard C, Gutierrez M, Kirova Y, Cherel P, Gachet J, Labib A, Mouret-Fourme E.

BMC Cancer. 2011 Sep 19;11:395. doi: 10.1186/1471-2407-11-395.

18.

Population-based outcomes after brain radiotherapy in patients with brain metastases from breast cancer in the Pre-Trastuzumab and Trastuzumab eras.

Karam I, Hamilton S, Nichol A, Woods R, Speers C, Kennecke H, Tyldesley S.

Radiat Oncol. 2013 Jan 9;8:12. doi: 10.1186/1748-717X-8-12.

19.

Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies.

Toi M, Iwata H, Fujiwara Y, Ito Y, Nakamura S, Tokuda Y, Taguchi T, Rai Y, Aogi K, Arai T, Watanabe J, Wakamatsu T, Katsura K, Ellis CE, Gagnon RC, Allen KE, Sasaki Y, Takashima S.

Br J Cancer. 2009 Nov 17;101(10):1676-82. doi: 10.1038/sj.bjc.6605343. Epub 2009 Oct 20.

20.

Comparison of overall survival between the early use and delayed use of Trastuzumab therapy groups: a retrospective analysis of 128 patients with HER-2-positive advanced breast cancer.

Shi YX, Tan YT, Yuan ZY, Wang SS, Peng RJ, An X, Cao Y, Jin Y, Cai XY, Sun YL, Teng XY, Liu DG.

Med Oncol. 2012 Mar;29(1):39-47. doi: 10.1007/s12032-010-9798-3. Epub 2011 Feb 8.

PMID:
21302001

Supplemental Content

Support Center